Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
  • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
  • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/17—Amino acids, peptides or proteins
  • A23L33/175—Amino acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/02—Nutrients, e.g. vitamins, minerals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents

Definitions

• the present invention relates to the field of nutrition; in particular to the prevention and/or treatment of malnutrition.
• One embodiment of the present invention relates to a nutritional composition enriched in cysteine for use in the treatment or prevention of malnutrition and disorders related thereto.
• Such a composition may in particular, but not exclusively, be useful for the elderly population.
• Anorexia is the decreased sensation of appetite. Many possible causes exist for a decreased appetite, some of which may indicate a serious clinical condition, or pose a significant risk. Oftentimes anorexia is a consequence of other illnesses. Under such circumstances malnutrition is a significant problem since it will delay the recovery process and may even prevent a full recovery.
• Anorexia is often present in the ageing population. Despite the increase in body fat and obesity that occurs with aging, there is a linear decrease in food intake over the life span. This may be explained by decreased physical activity and an altered metabolism with aging. Ageing-associated anorexia may have substantial adverse effects. The age-associated physiologic reduction in appetite and food intake has been termed “the anorexia of aging”. "Physiological' anorexia and weight loss of ageing predispose to pathological weight loss and malnutrition. This physiologic anorexia is caused for example by an altered hormonal and neurotransmitter regulation of food intake. Marked weight loss in the elderly drives morbidity and increased mortality, has a negative impact on the quality of life and contributes to frailty. Today, anorexia is often treated by administration of a variety of medicaments, some of which may have unwanted side effects .
• cysteine can be used, e.g. as part of a composition for enteral nutrition or a food product, to maintain or improve food intake, for example in the elderly.
• cysteine exhibits an anti-anorexic property, for example an anti ageing-associated anorexia property. Such effect was not observed with alanine- supplemented diet (control diet). To the inventor's best knowledge, this is the first description of a beneficial effect of cysteine on food intake. Consequently, providing cysteine-rich diet or adding cysteine to a food product, for example in a quantity higher than the normal requirement would allow counteracting the decrease in food consumption that occurs, e.g., in the elderly.
• anorexia e.g. chemotherapy, infection, anorexia nervosa, or stress conditions.
• cysteine may be used to treat or prevent anorexia and related conditions.
• cysteine may also be used in clinical products to control food intake, for example.
• one embodiment of the present invention is a nutritional composition enriched in cysteine.
• “Enriched” in cysteine means that cysteine was either added to a nutritional composition or that a food composition is treated in a way that its natural cysteine content per gram is increased.
• a composition is further considered “enriched” in cysteine if the composition contains cysteine in an amount that exceeds the recommended daily intake (RDI) .
• the recommended daily intake for cysteine for infants (0-12 months) is 45 mg/kg body weight; for children (1-17 years) 22 mg/kg body weight; and for adults (> 18 years) 10 mg/kg body weight.
• Cysteine may also be provided in the form of a cysteine precursor selected from the group consisting of cysteine bound in a protein or a peptide hydrolysate or a peptide, for example gamma-glutamyl-cysteine, or an ther form of peptide, for example gamma-glutamyl-cysteine ester, mixed disulfides such as L-cysteine-glutathione cysteine prodrugs, N-acetyl- cysteine (free form, amide or ester forms), S-allyl-cysteine, S-methyl-cysteine, S-ethyl-cysteine , S-propyl-cysteine, TCA ( thiazelidineScarboxylic acid) , OTC ( L-2-Oxothiazolidine-4- carboxylate) , bucillamine glutathione and glutathione esters (monomethyl, monoethyl, diethyl, iso
• the present invention also relates to the use of cysteine for the preparation of a composition to treat and/or prevent malnutrition and/or disorders related thereto.
• composition of the present invention may be additionally or alternatively for use in increasing food intake.
• composition of the present invention may also be used for decreasing satiety and/or satiation.
• the inventors found that the administration of the composition of the present invention allowed to significantly increase food intake.
• the composition of the present invention may also be used for increasing appetite.
• composition of the present invention allows increasing the willingness to eat as well as the total quantity of ingested food.
• any disorder related to malnutrition may be treated by administration of the composition of the present invention.
• the disorder related to malnutrition may be selected from the group consisting of anorexia, anorexia nervosa, cachexia, inflammatory diseases associated with decreased food intake, or combinations thereof.
• Low-grade inflammation appears to be an important parameter in the development of the homeosteny, for example associated with ageing.
• Age-associated low-grade inflammation may cause an increase mortality and morbidity, such as body weight loss.
• the present invention provides a new nutritional strategy to counterbalance such negative effects of low-grade inflammation that may occur in the elderly, for example.
• the composition may be to be administered to the elderly.
• a subject is considered as “elderly” or “aged” if it has surpassed the first half of its average expected lifespan in its country of origin, preferably, if it has surpassed the first two thirds of the average expected lifespan in its country of origin, more preferably if it has surpassed the first three quarters of the average expected lifespan in its country of origin, most preferred if it has surpassed the first four fifths of the average expected lifespan in its country of origin.
• composition of the present invention may be to be administered to a person at the age of at least 50 years, at least 60 years, at least 70 years or at least 80 years.
• composition of the present invention may also be to be administered to pets, for example aged pets.
• composition in accordance with the present invention may be for use in the treatment or prevention of an age related decrease in food intake.
• compositions of the present invention will typically contain a protein fraction, a lipid fraction and a carbohydrate fraction.
• the protein fraction may comprise at least 3.0 weight-%, at least 4 weight-%, at least 5 weight-%, at least 7 weight-% or at least 10 weight-% cysteine.
• a subject suffers from an impaired functioning of the gastro-intestinal tract, it may be preferred if for example at least in part a protein source is used that is pre-hydrolyzed.
• MCT medium chain triglycerides
• cysteine may typically be administered in a daily dose in the range of about 0.03 to 0.15 g/kg body weight, for example 0.05 to 0.12 g/kg body weight.
• the composition may contain cysteine in an amount of at least 2 g/kg dry weight, at least 4 g/kg dry weight, at least 6 g/kg dry weight, at least 8 g/kg dry weight, or at least 10 g/kg dry weight.
• cysteine from any source may be used in the framework of the present invention. Chemically pure cysteine has the advantage of being available in high purity and concentrations allowing a very precise dosing.
• cysteine may also be provided from natural sources.
• cysteine may be provided from animal sources such as pork, sausage meat, chicken, turkey, duck, luncheon meat, eggs, milk, milk proteins, whey protein, ricotta, cottage cheese, and/or yogurt; and/or from vegan sources such as red peppers, garlic, onions, broccoli, Brussels sprouts, oats, granola, and/or wheat germ.
• compositions of the present invention may have a caloric density of at least 0.5 kcal/g dry weight. Some people with an overall low food intake have problems to digest high caloric food. For such people low caloric formulations are preferred. Otherwise, increasing food intake has a more pronounced effect if food with a higher caloric density is consumed. Hence, the compositions of the present invention may also have a caloric density of at least 0.8 kcal/g dry weight, at least 1.0 kcal/g dry weight, at least 1.5 kcal/g dry weight, or at least 2.0 kcal/g dry weight.
• about 10 to 40 % of the calories of the composition may be from proteins.
• about 20 to 40 % of the calories of the composition are from proteins.
• the composition may also comprise about 15 to 45 % of the calories of the composition from lipids, and/or about 20 to 70 % of the calories of the composition from carbohydrates.
• the composition may be any kind of composition that is acceptable for human or animal consumption.
• the composition may be selected from the group consisting of a food product, a pet food product, a drink, a pharmaceutical, a nutritional formula, a composition for clinical nutrition, a nutritional powder to be reconstituted by addition of water, a juice or milk, a nutraceutical, a food additive, a food supplement, a dairy product, or a gel.
• Food additive or medicaments may be in the form of tablets, capsules, pastilles or a liquid for example.
• compositions may further contain protective hydrocolloids (such as gums, proteins, modified starches), binders, film forming agents, encapsulating agents/materials, wall/shell materials, matrix compounds, coatings, emulsifiers, surface active agents, solubilizing agents (oils, fats, waxes, lecithins etc. ) , adsorbents, carriers, fillers, co-compounds, dispersing agents, wetting agents, processing aids (solvents), flowing agents, taste masking agents, weighting agents, jellifying agents, gel forming agents, antioxidants and antimicrobials .
• protective hydrocolloids such as gums, proteins, modified starches
• binders film forming agents, encapsulating agents/materials, wall/shell materials, matrix compounds, coatings, emulsifiers, surface active agents, solubilizing agents (oils, fats, waxes, lecithins etc. ) , adsorbents, carriers, fillers, co-
• They may also contain conventional pharmaceutical additives and adjuvants, excipients and diluents, including, but not limited to, water, gelatine of any origin, vegetable gums, ligninsulfonate, talc, sugars, starch, gum arabic, vegetable oils, polyalkylene glycols, flavouring agents, preservatives, stabilizers, emulsifying agents, buffers, lubricants, colorants, wetting agents, fillers, and the like.
• conventional pharmaceutical additives and adjuvants, excipients and diluents including, but not limited to, water, gelatine of any origin, vegetable gums, ligninsulfonate, talc, sugars, starch, gum arabic, vegetable oils, polyalkylene glycols, flavouring agents, preservatives, stabilizers, emulsifying agents, buffers, lubricants, colorants, wetting agents, fillers, and the like.
• composition may be to be administered orally, enterally or parenterally.
• oral administration is preferred, since it can be easily done at home, and would consequently allow using the subject matter of the present invention in a private atmosphere. Everybody could easily have access to and use the compositions of the present invention, optionally after consultation with medical personnel.
• enteral administration of the compositions of the present invention may be a preferred option, for example as tube feeding formulation. If oral and/or enteral administration is not possible or not recommended, parenteral administration may be used. Hence, the composition of the present invention may also be in a form suitable for parenteral administration. Such compositions often do not contain a carbohydrate source, for example.
• composition may be to be administered as a meal or in the framework of a meal.
• composition may also to be administered within one hour before or during a meal, for example. As such it may serve as a functional appetizer, for example.
• Figure 1 summarized the experimental design.
• Figure 2 shows Kaplan-Meier survival curves of old rats fed with an alanine (A) and a cysteine (C) diet.
• Figure 3 shows the effect of cysteine supplementation on body weight.
• a to h time points not sharing a common letter are significantly different (Fisher's PLSD, P ⁇ 0.05).
• Figure 4 shows the effect of cysteine supplementation on food intake.
• a to 1 time points not sharing a common letter are significantly different (Fisher's PLSD, P ⁇ 0.05).
• a cohort of male Wistar rats born and breed in a non-specific- pathogen-free animal facility (Unite de Nutrition Comparee, INRA Theix) was used for the study. When rats were 18 month old they were weighted monthly to evaluate their body weight change and blood was sampled in order to quantify inflammatory markers (acute phase proteins: 2-macro gl obul i n and fibrinogen) . At the age of 21 months, rats were divided in two groups matched for body weight, body weight loss, and inflammatory status. Rats were fed with supplemented diets, starting at the age of 21 months and for 14 weeks.
• the cysteine diet consisted in the commercial pelleted diet A04 (SAFE/UAR, Scientific Animal Food and Engineering, Villemoisson-sur-Orge, France) supplemented with 4.0 g of L- cysteine (Sigma) per kg, and the control diet was supplemented with 2.9 g of L-alanine (Jerafrance) per kg ( iso-nitrogenous diets) .
• Experimental diets have been prepared at the Unite Preparation Aliments Experimentaux, INRA Jouy-en-Josas .
• the amino acid composition of the commercial (non-supplemented) diet is presented in Table 1. Table 1. Amino acid composition of the commercial diet (A04 ) .
• Body weight (Fig 3) decreased with time and it became significantly different from the initial value at 7 weeks of supplementation. The decrease accelerated at the end of the experiment since body weights of the two last weeks were different from each of the previous ones.
• cysteine supplemented rats exhibited a higher liver weight than control rats.
• BW body weight

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Nutrition Science (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Epidemiology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Polymers & Plastics (AREA)
• Obesity (AREA)
• Hematology (AREA)
• Diabetes (AREA)
• Mycology (AREA)
• Food Science & Technology (AREA)
• Child & Adolescent Psychology (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Feed For Specific Animals (AREA)
• Fodder In General (AREA)

Priority Applications (14)

Applications Claiming Priority (2)

Publications (1)

Family

ID=43304791

Family Applications (1)

Country Status (15)

Cited By (1)

Families Citing this family (6)

Citations (9)

Family Cites Families (11)

• 2010
  • 2010-10-21 EP EP10188399A patent/EP2444083A1/en not_active Withdrawn
• 2011
  • 2011-10-19 AU AU2011317627A patent/AU2011317627B2/en active Active
  • 2011-10-19 EP EP11770786.9A patent/EP2629769B1/en active Active
  • 2011-10-19 CN CN2011800614347A patent/CN103269697A/zh active Pending
  • 2011-10-19 RU RU2013123062/15A patent/RU2013123062A/ru not_active Application Discontinuation
  • 2011-10-19 US US13/880,923 patent/US9233090B2/en active Active
  • 2011-10-19 JP JP2013534304A patent/JP6160832B2/ja active Active
  • 2011-10-19 ES ES11770786.9T patent/ES2654344T3/es active Active
  • 2011-10-19 SG SG2013029574A patent/SG189935A1/en unknown
  • 2011-10-19 CA CA2815109A patent/CA2815109C/en active Active
  • 2011-10-19 WO PCT/EP2011/068231 patent/WO2012052463A1/en not_active Ceased
  • 2011-10-19 MX MX2013004371A patent/MX2013004371A/es not_active Application Discontinuation
  • 2011-10-19 BR BR112013009709A patent/BR112013009709A2/pt not_active Application Discontinuation
  • 2011-10-19 DK DK11770786.9T patent/DK2629769T3/en active
  • 2011-10-19 PH PH1/2013/500761A patent/PH12013500761A1/en unknown
• 2013
  • 2013-05-20 ZA ZA2013/03656A patent/ZA201303656B/en unknown

Patent Citations (10)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events